Filing Analysis
Other SEC Filing
Filed May 07, 2026
LOW
Black Diamond Therapeutics, Inc. (BDTX) reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the 8-K filing.
Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The report was filed on May 7, 2026, which is also the date of the earliest event reported.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full press release with the financial announcement.
Regulation FD Disclosure
Filed Mar 16, 2026
LOW
Black Diamond Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025. The disclosure was made through a press release furnished as an exhibit to the filing.
Key Facts
- Financial results reported for the fiscal year ended December 31, 2025.
- Financial results reported for the three months ended December 31, 2025.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Brent Hatzis-Schoch, COO and General Counsel.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.